Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Monte Rosa Therapeutics (GLUE) Equity Ratio: 2023-2025

Historic Equity Ratio for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Sep 2025 value amounting to 0.53.

  • Monte Rosa Therapeutics' Equity Ratio fell 18.01% to 0.53 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.53, marking a year-over-year decrease of 18.01%. This contributed to the annual value of 0.51 for FY2024, which is 13.89% down from last year.
  • As of Q3 2025, Monte Rosa Therapeutics' Equity Ratio stood at 0.53, which was down 28.29% from 0.75 recorded in Q2 2025.
  • Monte Rosa Therapeutics' Equity Ratio's 5-year high stood at 0.79 during Q1 2023, with a 5-year trough of 0.51 in Q4 2024.
  • Its 3-year average for Equity Ratio is 0.66, with a median of 0.65 in 2024.
  • As far as peak fluctuations go, Monte Rosa Therapeutics' Equity Ratio declined by 27.50% in 2024, and later rose by 22.39% in 2025.
  • Quarterly analysis of 3 years shows Monte Rosa Therapeutics' Equity Ratio stood at 0.59 in 2023, then fell by 13.89% to 0.51 in 2024, then declined by 18.01% to 0.53 in 2025.
  • Its Equity Ratio stands at 0.53 for Q3 2025, versus 0.75 for Q2 2025 and 0.70 for Q1 2025.